What do the top 10 biotech M&A deals of 2020 tell us? Pre­mi­ums are in, bolt-ons rule and the ADC come­back is on

Last year the M&A spot­light in bio­phar­ma cen­tered on big mon­ey and some large ap­petites for pipeline and port­fo­lio re­struc­tur­ing. This year is all about bolt-ons and the care­ful de­vour­ing of new pipeline as­sets.

A few weeks ago we asked the in­com­pa­ra­ble Chris Doko­ma­ji­lar, who heads Deal­For­ma, to run a cut of the num­bers on all the biotech M&A deals of any con­se­quence for 2020. Be­low, you’ll find every­thing above the $50 mil­lion low-wa­ter mark.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.